natgillin/translations-raw huggingface dataset:
Cattle: forbidden in lactating cows, not to be administered less than 60 days before calving Sheep: forbidden in lactating sheep, not to be administered less than 70 days before lambing 
Ovce: Prepovedana uporaba pri ovcah molznicah ter brejih ovcah molznicah v času 70 dni pred jagnjitvijo.
Cattle, sheep and pigs Single dose 
Dectomax Raztopina za injiciranje govedo, ovce in prašiči enkratni odmerek govedo in ovce:
Not to be used in cattle producing milk for human consumption. 
Ni namenjeno zdravljenju živali, ki proizvajajo mleko za prehrano ljudi.
Not for use in pregnant ewes Pigs 
Ni namenjeno uporabi v brejih ovcah.
Cattle and reindeer: 42 days Sheep: 45 days (im), 60 days (sc)Nematodirus battus 55 days (im), 70 days (sc) 
), 60 dni (s.c.)Nematodirus battus 55 dni (i.m.
Cattle: Not to be used for pregnant cows 60 days before giving birth. 
Govedo: Uporaba pri brejih kravah v času 60 dni pred otelitvijo ni dovoljena.
Cattle, Reindeer, Pigs Not permitted for use in animals producing milk for human consumption during lactation 
Dectomax Vet govedo, severna jelenjad, prašiči Zdravljenje živali, ki priozvajajo mleko za prehrano ljudi, ni dovoljena.
200 g/kg bw (sc, im), (Nematodirus 300 g/kg bw (sc, im)) Pigs: 
), (Nematodirus 300 g/kg telesne teže (s.c., i.m.))
Strength Pharmaceutical Form 
Farmacevtska oblika Pot uporabe Stična ovojnina
EU (MA) Number 
Številka (EU) dovoljenja za promet
Packaging Content Package size 
Pakiranje Vsebina Velikost pakiranja
EU (MA) Number 
EU (MA) številka Izmišljeno ime
Route of administration 
Način uporabe
Prior to the launch in each Member State, the Marketing Authorisation Holder shall agree with the National Competent Authority the format and content of the Physician Educational Materials and must implement such programme nationally to ensure that, prior to prescribing, all physicians are provided with a healthcare information pack containing: 
Pred začetkom trženja v vsaki državi članici se mora imetnik dovoljenja za promet z zdravilom dogovoriti z nacionalnim pristojnim organom glede formata in vsebine izobraževalnega gradiva za zdravnike ter dogovorjeni program vpeljati nacionalno tako, da pred predpisovanjem zagotovi, da vsi zdravniki prejmejo paket informacij za zdravnike, ki vsebuje:
- Summary of Product Characteristics (in full) 
- Povzetek glavnih značilnosti zdravila (v celoti),
The member States must ensure that all conditions with regard to the safe and effective use of the medicinal product described below are implemented. 
Države članice morajo zagotoviti uveljavitev vseh spodaj opisanih pogojev glede varne in učinkovite uporabe zdravila.
Key elements to be included in the educational material: 
Izobraževalno gradivo za zdravnike mora vsebovati naslednje ključne podatke:
• Detailed information about the risk of haematological disorders (notably anaemia) associated with Victrelis, consisting of factual description of the haematological disorders in terms of frequency and time to onset and related clinical symptoms. 
• Natančne informacije o tveganju za hematološke motnje (še posebej anemijo) povezane z zdravilom Victrelis.
The final study report shall be submitted by 31 December 2021. 
Končno poročilo o študiji bo predloženo do 31. decembra 2021.
• what dose to take and for how long. 
• kakšen odmerek morate jemati in kako dolgo;
Your doctor will tell you: 
Zdravnik vam bo povedal:
The potential risk for humans is unknown. 
Morebitno tveganje za človeka ni znano.
Do not change the dose yourself. 
Odmerka ne spreminjajte sami.
The usual dose that you will need to take is listed below. 
Običajni odmerek, ki ga morate vzeti, je naveden spodaj.
3 years. 
3 leti
The objectives of the study are: 
Cilji študije so:
Treatment and monitoring recommendations* 
Priporočila za zdravljenje in spremljanje*
• when to increase or decrease your dose. 
• kdaj povečati ali zmanjšati odmerek.
• Advice to patients about: 
• Nasvet bolnikom glede:
Not known (frequency cannot be estimated from the available data) 
Neznana pogostnost (pogostnosti iz razpoložljivih podatkov ni mogoče oceniti)
There are no reliable data on its use in pregnant women. 
Zanesljivih podatkov o uporabi pri nosečnicah ni.
o statins such as simvastatin. 
o statini, kot je simvastatin.
Parameter/Abnormality 
Parameter/abnormalnost
• Confirm elevation with a repeat measurement within one week. 
• Potrdite povišanje s ponovno meritvijo v roku enega tedna.
*Recommendations based on an ULN of approximately 30-40 international units/L. 
* Priporočila temeljijo na vrednosti ULN, ki je približno 30-40 mednarodnih enot/l.
This being an approval under exceptional circumstances and pursuant to Article 14(8) of Regulation (EC) No 726/2004, the MAH shall conduct, within the stated timeframe, the following measure: 
Ker gre za odobritev v izjemnih okoliščinah in ob upoštevanju člena 14(8) Uredbe (ES) št. 726/2004, mora imetnik dovoljenja za promet v določenem časovnem okviru izvesti naslednje ukrepe:
Annual reports will be submitted at time of annual reassessment 
Letna poročila se bodo priložila v času ponovne letne ocene.
Statins occasionally cause myopathy. 
Statini občasno povzročajo miopatijo.
• Advice to patients about the risk of concomitant alcohol intake; 
• Nasvet za bolnike o tveganju sočasnega uživanja alkohola;
Age and gender 
Starost in spol
• Pregnancy (see section 4.6). 
• nosečnost (glejte poglavje 4.6).
• blood or protein in the urine 
• kri ali beljakovine v urinu,
If you feel dizzy during treatment then do not drive or use machines until you feel better. 
Če ste med zdravljenjem omotični, ne uporabljajte vozil ali strojev, dokler se ne počutite bolje.
Twenty-nine patients were enrolled, of whom 23 completed through Week 78. 
Vključenih je bilo devetindvajset bolnikov, od katerih jih je 23 zaključilo 78. teden.
Date of latest renewal: 23 April 2018 
Datum prve odobritve: 31. julij 2013 Datum zadnjega podaljšanja: 23. april 2018
The study provided for a total of 78 weeks of treatment. 
Študija je skupno vključevala 78 tednov zdravljenja.
Because of the possibility of interactions with other medicines, your doctor may change the time of day you take your medicines. 
Zaradi možnih interakcij z drugimi zdravili lahko zdravnik spremeni čas v dnevu, ko boste zdravilo jemali.
Consequently, this would reduce the effect of lomitapide. 
Posledično bo to zmanjšalo učinek lomitapida.
• All capsules have edible black ink for printing. 
• Vse kapsule vsebujejo užitno črnilo za tiskanje.
These blood tests help your doctor adjust your dose. 
Krvne preiskave zdravniku pomagajo prilagajati vaš odmerek.
Any impact on efficacy is likely to be variable. 
Verjetno je, da bo vpliv na učinkovitost variabilen.
Study Week 
Teden v študiji
The risk of liver damage is increased when this medicine is used at the same time as statins. 
Tveganje jetrne poškodbe se poveča, če se to zdravilo uporablja sočasno s statini.
>5% to ≤10% >10% to ≤15% >15% to ≤20% >20% to ≤25% 
> 5 % do ≤ 10 % > 10 % do ≤ 15 % > 15 % do ≤ 20 % > 20 % do ≤ 25 %
• tiredness, lack of energy or general weakness 
• utrujenost, pomanjkanje energije ali splošna šibkost,
These capsules may cause side effects which can also be symptoms of liver problems. 
Te kapsule lahko povzročijo neželene učinke, ki lahko vključujejo tudi simptome težav z jetri.
The MAH must agree the content and format of the educational materials together with a communication plan with the national competent authority in each Member State prior to distribution in their territory. 
Imetnik dovoljenja za promet z zdravilom se mora o vsebini in obliki izobraževalnih gradiv skupaj s komunikacijskim načrtom dogovoriti skupaj z nacionalnim pristojnim organom v posamezni državi članici pred distribucijo na njenem ozemlju.
The performance of these tests and their interpretation should involve collaboration between the treating physician and the hepatologist. 
Izvedba teh preiskav in njihova interpretacija morata vključevati sodelovanje lečečega zdravnika ter hepatologa.
The elimination half-life of lomitapide was approximately 29 hours. 
Razpolovni čas izločanja lomitapida je bil približno 29 ur.
This means that due to the rarity of the disease it has not been possible to obtain complete information on this medicinal product. 
To pomeni, da zaradi redkosti bolezni ni bilo mogoče pridobiti vseh podatkov o zdravilu.
Inform your doctor of any change in the medicines you are taking. 
Zdravnika obvestite o vseh spremembah zdravil, ki jih jemljete.
Appropriate patient selection 
Ustrezna izbira bolnikov
Alcohol may increase levels of hepatic fat and induce or exacerbate liver injury. 
Alkohol lahko poviša ravni maščob v jetrih in povzroči ali poslabša jetrno poškodbo.
There was no clinically relevant effect of age (18-64 years) or gender on the pharmacokinetics of lomitapide. 
Klinično pomembnega učinka starosti (18-64 let) ali spola na farmakokinetiko lomitapida ni bilo.
Educational materials for patients 
Izobraževalno gradivo za bolnike
The dose of warfarin should be adjusted as clinically indicated. 
Odmerek varfarina je treba prilagoditi, kot je klinično indicirano.
It should be taken on an empty stomach, at least 2 hours after the evening meal because the fat content of a recent meal may adversely impact gastrointestinal tolerability. 
Zaužiti ga je treba na prazen želodec vsaj 2 uri po večernem obroku, saj lahko vsebnost maščob v zadnjem obroku neželeno učinkuje na gastrointestinalno toleranco.
The Prescriber Guide shall include the following key elements: 
Navodila za predpisovanje morajo vsebovati naslednje ključne elemente:
Approximately 33% of the radioactivity was excreted in urine as metabolites. 
Približno 33 % radioaktivnosti se je izločilo z urinom v obliki presnovkov.
• The need to inform their doctor if they have had any liver problems in the past; 
• Potrebo po obveščanju svojega zdravnika o kakršnih koli težavah z jetri v preteklosti;
Women who become pregnant should be counselled and referred to an expert in teratology; 
Ženskam, ki zanosijo, je treba ponuditi svetovanje in jih napotiti k strokovnjaku za teratologijo;
It is important to avoid dehydration by drinking enough fluids (see section 4). 
Pomembno je preprečiti dehidracijo z zadostnim pitjem tekočin (glejte poglavje 4).
Store below 30°C. 
Shranjujte pri temperaturi pod 30 °C.
Fifteen of 23 (65%) patients had their lipid-lowering treatment reduced by Week 78, including planned and unplanned reductions/interruptions. 
Pri 15 od 23 (65 %) bolnikov so se odmerki zdravil za zniževanje ravni lipidov do 78. tedna zmanjšali, vključno z načrtovanimi in nenačrtovanimi zmanjšanji/prekinitvami.
• Women should tell their doctor immediately if they suspect that they might be pregnant. 
• Ženske se morajo takoj posvetovati s svojim zdravnikom, če menijo, da bi bile lahko noseče.
Patients on 5 mg should remain on 5 mg. 
Bolniki na odmerku 5 mg morajo na odmerku 5 mg ostati.
• The need to inform their doctor of all other medicines they are taking as special care should be taken if other medicines which can cause liver problems are taken at the same time; 
• Potrebo po obveščanju zdravnika o vseh drugih zdravilih, ki jih jemljejo, saj je treba biti še posebej previden, če se sočasno jemljejo zdravila, ki lahko povzročijo težave z jetri;
Absorption is not limited by penetration of the active substance across the intestinal barrier but is predominantly influenced by an extensive first pass effect. 
Absorpcija ni omejena na prehajanje učinkovine prek črevesne pregrade, ampak nanjo večinoma vpliva učinek obsežnega prvega prehoda.
Sixteen males (55%) and 13 females (45%) were included with a mean age of 30.7 years, ranging from 18 to 55 years. 
16 moških (55 %) in 13 žensk (45 %) s povprečno starostjo 30,7 leta, tj. od 18 do 55 let.
If you stop taking this medicine your cholesterol may rise again. 
Če prenehate jemati to zdravilo, se lahko ravni holesterola spet povišajo.
Week 78 (N=23) 
78. teden (N = 23)
It is typically passed down by both father and mother, who also have high cholesterol passed down from their parents. 
Navadno se prenese z očeta in matere, ki sta visoke ravni holesterola podedovala od svojih staršev.
• Do not drink any type of grapefruit juice. 
• Ne uživajte soka grenivke v nobeni obliki.
Information that the educational materials for patients included in the prescribers pack can be used for patient counselling. 
Informacije, da se lahko izobraževalno gradivo za bolnike, priloženo kompletu za zdravnike, uporabi za svetovanje bolnikom.
Genetic confirmation of HoFH should be obtained whenever possible. 
Kadar je mogoče, je treba HoFH potrditi z genetskimi preiskavami.
• The safety and effectiveness of Lojuxta in children below the age of 18 have not been established; 
• Varnost in učinkovitost zdravila Lojuxta pri otrocih, mlajših od 18 let, nista bili dokazani;
In the Phase 3 study, 3 of 4 patients with ALT elevations >5x ULN reported alcohol consumption beyond the limits recommended in the protocol. 
V študiji 3. faze so 3 od 4 bolnikov s povišanjem ravni ALT > 5-kratna vrednost ULN poročali o uživanju alkohola zunaj omejitev, priporočenih v protokolu.
• total cholesterol 
• celokupnega holesterola;
In the event of overdose, the patient should be treated symptomatically and supportive measures instituted as required. 
V primeru prevelikega odmerjanja je treba bolnika zdraviti simptomatsko in po potrebi uvesti podporne ukrepe.
Lancaster Way, Wingates Industrial Estate, Westhoughton, Bolton, Lancashire, BL5 3XX United Kingdom 
Lancaster Way, Wingates Industrial Estate, Westhoughton, Bolton, Lancashire, BL5 3XX Velika Britanija
These changes are secondary to the mechanism of action of lomitapide. 
Te spremembe so posledica mehanizma delovanja lomitapida.
• To evaluate the long-term effectiveness of lomitapide in maintaining control of serum lipid levels in clinical practice. 
• Oceniti dolgotrajno učinkovitost lomitapida pri vzdrževanju ravni lipidov v serumu v klinični praksi.
In animal studies lomitapide was highly concentrated (200-fold) in the liver. 
V študijah na živalih je bil lomitapid izjemno koncentriran (200-kratno) v jetrih.
• if you are pregnant, trying to get pregnant, or think you may be pregnant (see section 2 under ‘Pregnancy and breast-feeding'). 
• če ste noseči, načrtujete zanositev ali menite, da bi lahko bili noseči (glejte poglavje 2 „Nosečnost in dojenje“).
• To lower the chance of stomach problems, you must stay on a low-fat diet whilst taking this medicine. 
• Da zmanjšate možnost želodčnih težav, morate med jemanjem tega zdravila vzdrževati dieto z majhnim vnosom maščob.
Doses higher than 60 mg suggest a trend toward nonlinearity and are not recommended. 
Odmerki, večji od 60 mg, kažejo nelinearnost in niso priporočljivi.
The printed package leaflet of the medicinal product must state the name and address of the manufacturer responsible for the release of the concerned batch. 
V natisnjenem navodilu za uporabo zdravila morata biti navedena ime in naslov izdelovalca, odgovornega za sprostitev zadevne serij
The liver enzyme changes can occur at any time during therapy, but occur most often during dose escalation. 
Spremembe jetrnih encimov se lahko pojavijo kadarkoli med zdravljenjem, vendar najpogosteje med povečevanjem odmerka.
• Do not take this medicine with food, as taking these capsules with food can cause stomach problems. 
• Tega zdravila ne jemljite skupaj s hrano, saj lahko povzroči želodčne težave.
Median presented for TG and Lp(a). 
a Mediana, predstavljena za TG in Lp(a).
In the renal impairment population, lomitapide was only studied in patients with end-stage renal disease (ESRD). 
Glede populacije z ledvično okvaro se je lomitapid preučeval samo pri bolnikih z ledvično boleznijo v končnem stadiju (ESRD).
Effects on lomitapide levels 
Učinki na ravni lomitapida
The physician educational pack should contain: 
Izobraževalni komplet za zdravnike mora vsebovati:
Frequency of the adverse reactions is defined as: very common (1/10), common (1/100 to <1/10), uncommon (1/1,000 to <1/100), rare (1/10,000 to <1/1,000), very rare (<1/10,000), not known (cannot be estimated from the available data). 
občasni (≥ 1/1.000 do < 1/100), redki (≥ 1/10.000 do < 1/1.000), zelo redki (< 1/10.000), neznana pogostnost (ni mogoče oceniti iz razpoložljivih podatkov).
The European Medicines Agency has deferred the obligation to submit the results of studies with Lojuxta in one or more subsets of the paediatric population in HoFH (see section 4.2 for information on paediatric use). 
Evropska agencija za zdravila je začasno odložila zahtevo za predložitev rezultatov študij z zdravilom Lojuxta za eno ali več podskupin pediatrične populacije pri HoFH (za podatke o uporabi pri pediatrični populaciji glejte poglavje 4.2).
(dehydration) 
(dehidracija).
These capsules should be given to you by a doctor experienced in the treatment of lipid disorders who will also monitor you regularly. 
Te kapsule vam mora predpisati zdravnik z izkušnjami z zdravljenjem lipidnih motenj, ki vas bo redno spremljal.
Following intravenous administration, the volume of distribution of lomitapide was high (mean=1200 litres) despite a high degree (>99.8%) of binding to plasma protein. 
Po intravenskem dajanju je bil volumen porazdelitve lomitapida velik (povprečno 1200 litrov) kljub veliki stopnji (> 99,8 %) vezave na beljakovine v plazmi.
In the Phase 3 study, patients were provided daily dietary supplements of vitamin E, linoleic acid, ALA, EPA and DHA. 
V študiji 3. faze so bolniki prejemali dnevne prehranske dodatke vitamina E, linolne kisline, ALA, EPA in DHA.
If your tests show some liver problems, your doctor may decide to reduce your dose or stop the treatment. 
Če preiskave pokažejo težave z jetri, se bo zdravnik morda odločil, da zmanjša odmerek ali prekine zdravljenje.
• Gamma-GT and serum albumin to detect possible liver injury 
• vrednost gama-GT in albumina v serumu za ugotavljanje morebitne jetrne poškodbe;
Your doctor may increase your dose slowly over time, up to a maximum of 60 mg each day. 
Zdravnik lahko postopoma in počasi odmerek povečuje do največ 60 mg na dan.
The purpose of the patient alert card is to inform health care professionals of potential drug-drug interactions before any additional medicinal product is prescribed. 
Namen opozorilne kartice za bolnika je zdravnike obveščati o morebitnih interakcijah med zdravili, preden predpišejo katero koli dodatno zdravilo.
• Lojuxta is only indicated for use in adult patients with HoFH; 
• Zdravilo Lojuxta je indicirano samo pri odraslih bolnikih s HoFH;
Keep the bottle tightly closed in order to protect from moisture. 
Plastenko shranjujte tesno zaprto za zagotovitev zaščite pred vlago.
• If, after you have started treatment with Lojuxta, you decide that you would like to become pregnant, please inform your doctor, as your treatment will need to be changed. 
• Če se po začetku zdravljenja z zdravilom Lojuxta odločite, da bi radi zanosili, se o tem posvetujte s svojim zdravnikom, saj bo treba spremeniti zdravljenje.
Patients should avoid consumption of grapefruit juice (see sections 4.4 and 4.5). 
Bolniki se morajo izogibati uživanju soka iz grenivke (glejte poglavji 4.4 in 4.5).
• At the request of the European Medicines Agency; • Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached. 
• ob vsakršni spremembi sistema za obvladovanje tveganj, zlasti kadar je tovrstna sprememba posledica prejema novih informacij, ki lahko privedejo do znatne spremembe razmerja med koristmi in tveganji, ali kadar je ta sprememba posledica tega, da je bil dosežen pomemben mejnik (farmakovigilančni ali povezan z zmanjševanjem tveganja).
Because of the potential for adverse effects based on findings in animal studies with lomitapide (see section 5.3), a decision should be made whether to discontinue breast-feeding or discontinue the medicinal product, taking into account the importance of the medicinal product to the mother. 
Zaradi potenciala za neželene učinke, ki so jih opazili v študijah z lomitapidom na živalih (glejte poglavje 5.3), se je treba odločiti za prekinitev dojenja ali jemanja zdravila, pri čemer je treba upoštevati koristi zdravila za mater.
Tell your doctor or pharmacist if you are taking any of the following medicines: 
Obvestite svojega zdravnika ali farmacevta, če jemljete katero koli od naslednjih zdravil:
The maximum dose administered to human subjects in clinical studies was 200 mg as a single dose; there were no adverse reactions. 
Največji odmerek, ki se je uporabil pri ljudeh v kliničnih študijah, je bil 200 mg v obliki enkratnega odmerka; pri tem ni bilo nobenih neželenih učinkov.
• Warning about possible loss of effectiveness of oral contraceptives due to diarrhoea or vomiting and need for additional contraception until 7 days after resolution of symptoms; 
• Opozorilo o morebitni izgubi učinkovitosti peroralnih kontracepcijskih sredstev zaradi diareje ali bruhanja in potrebi po dodatni kontracepciji 7 dni po izginotju simptomov;
Lomitapide does not inhibit breast cancer resistance protein (BCRP). 
Lomitapid ne zavira rezistentnega proteina pri raku dojke (BCRP).
Do not use this medicine after the expiry date which is stated on the label or carton after “EXP”. 
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na nalepki ali škatli poleg oznake „Uporabno do“.
• Before initiating treatment in women of child-bearing potential: 
• Pred uvedbo zdravljenja pri ženskah v rodni dobi:
The patient's “bad” cholesterol level is very high from a very early age. 
„slabega“ holesterola so visoke že v zgodnjih letih življenja.
≥3x and <5x Upper Limit of Normal (ULN) 
≥ 3-krat in < 5-krat zgornja meja normalne vrednosti (ULN
Mean percent change from baseline through Week 26 using last observation carried forward (LOCF) to each assessment is shown in Figure 1. 
Povprečna odstotna sprememba od izhodišča do 26. tedna z uporabo prenosa zadnjega opažanja (LOCF) za vsako oceno je prikazana na sliki 1.
• if you have bowel problems or cannot absorb food from your bowel. 
• če imate črevesne težave ali ne morete absorbirati hrane iz črevesa;
You must also tell your doctor or pharmacist if you are taking any of the following medicines, as they may need to change your dose of Lojuxta: 
Prav tako obvestite zdravnika ali farmacevta, če jemljete katero koli od naslednjih zdravil, saj bo zdravnik morda moral spremeniti vaš odmerek zdravila Lojuxta:
The most common adverse reactions were gastrointestinal effects. 
Najpogostejši neželeni učinki so bili učinki na prebavila.
Changes in lipids and lipoproteins through Week 26 and Week 78 of lomitapide treatment are presented in Table 5. 
Spremembe lipidov in lipoproteinov od 26. do 78. tedna pri zdravljenju z lomitapidom so predstavljene vPreglednici 5.
• Decrease the dose of Lojuxta by half. 
• je treba odmerek zdravila Lojuxta zmanjšati za polovico.
The absolute oral bioavailability of lomitapide is 7%. 
Absorpcija Absolutna peroralna biološka uporabnost lomitapida je 7 %.
• antacids (e.g. ranitidine, cimetidine) 
• antacidi (npr. ranitidin, cimetidin),
Your doctor will give you a blood test to check your liver before you start taking these capsules, if your dose is increased, and regularly during treatment. 
Zdravnik bo krvno preiskavo, s katero bo preveril delovanje jeter, opravil pred začetkom jemanja teh kapsul, ob povečanju odmerka in potem redno med zdravljenjem.
The mean dose of lomitapide was 45 mg at Week 26 and 40 mg at Week 78. 
Povprečen odmerek lomitapida je bil 45 mg v 26. tednu in 40 mg v 78. tednu.
Serious side effects: 
Resni neželeni učinki:
The effect of Lojuxta on cardiovascular morbidity and mortality has not been determined. 
Učinka zdravila Lojuxta na kardiovaskularno obolevnosti in umrljivosti niso ugotovili.
• apolipoprotein-B, a protein that carries “bad cholesterol” in the blood 
• apolipoproteina B, proteina, ki prenaša „slab holesterol“ po krvi;